The Federal Republic of Germany will invest €300 million in the biopharmaceutical company CureVac AG, for the further development of the company’s pipeline and mRNA platform technology and the expansion of business activities. 

The investment will be made by the Kreditanstalt für Wiederaufbau (KfW), and the funds from the capital increase will be used by CureVac. Under the agreement, the KfW will hold a stake of around 23 percent in CureVac.

Dr. Franz-Werner Haas, acting Chief Executive Officer and Chief Operating Officer of CureVac AG, said, “We are very excited that, with the Federal Republic of Germany and dievini, we have such strong and reliable partners at our side. This strong financial commitment provides us further cash reach and stability for the accelerated development of our mRNA platform, the development and production of our current and additional mRNA vaccine and drug candidates, as well as the strategic expansion of our organization. At the same time we will retain full operational and strategic independence.”